As shown in Fig. 1c,d, LLGL2low/SLC7A5low showed longer survival compared with high LLGL2/SLC7A5 mRNA co-expression (LLGL2high/SLC7A5high) and a positive trend of longer survival compared with other combination groups in ERα-positive breast cancer patients. This evidence concerns the gene SLC7A5 and breast carcinoma.